Inflammation in Heart Failure

Murphy et al. (Sun,) conducted a review in Heart failure. Anti-inflammatory therapies was evaluated. Targeted anti-inflammatory therapies may improve prognosis in specific heart failure phenotypes driven by inflammatory pathobiology, despite previous clinical trials proving mostly unsuccessful.

www.synapsesocial.com/papers/69f178a0adb7394e289b4893 — DOI: https://doi.org/10.1016/j.jacc.2020.01.014

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Neprilysin Inhibitor–Angiotensin II Receptor Blocker Combination Therapy (Sacubitril/valsartan) Suppresses Atherosclerotic Plaque Formation and Inhibits Inflammation in Apolipoprotein E- Deficient Mice· 2019 · 36 citations
2. Mast Cells Cause Apoptosis of Cardiomyocytes and Proliferation of Other Intramyocardial Cells In Vitro· 1999 · 119 citations
3. Immunoglobulin-free light chains elicit immediate hypersensitivity-like responses· 2002 · 190 citations
4. Plasma Cytokine Parameters and Mortality in Patients With Chronic Heart Failure